Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnostic performance of angiography-derived coronary physiology in transcatheter aortic valve implantation pathway: a systematic review and diagnostic accuracy meta-analysis.

The Journal of invasive cardiology·2026

Same author

Management of Spontaneous Coronary Dissection Complicated by Cardiogenic Shock: A Case Report.

Clinical case reports·2026

Same author

Protected percutaneous coronary intervention of complex distal left main disease with Impella CP™ support.

European heart journal supplements : journal of the European Society of Cardiology·2026

Same author

Patient selection for complex, high-risk indicated percutaneous coronary intervention procedures: an overview.

European heart journal supplements : journal of the European Society of Cardiology·2026

Same author

Myocardial Perfusion and Fluorodeoxyglucose Uptake Patterns in Cardiac Sarcoidosis Stratified by Diagnostic Category and Systemic Involvement.

Circulation journal : official journal of the Japanese Circulation Society·2026

Same author

Impact of obesity on 1-year major adverse cardiac events after primary PCI for STEMI.

International journal of cardiology·2026

Search research articles

Related Experiment Video

Updated: Sep 27, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Ventricular Unloading Using the Impella^TM Device in Cardiogenic Shock.

Adrian Attinger-Toller¹, Matthias Bossard¹, Giacomo Maria Cioffi¹

¹Cardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.

Frontiers in Cardiovascular Medicine

|April 11, 2022

Summary

Cardiogenic shock (CS) management is evolving with mechanical circulatory support. The Impella device offers ventricular unloading to improve heart function and patient outcomes, though more randomized trials are needed.

Keywords:

Impella cardiogenic shock expert group hemodynamics mechanical circulatory support device review ventricular unloading

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Sep 27, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

Cardiology
Medical Devices
Critical Care Medicine

Background:

Cardiogenic shock (CS) is a significant cause of in-hospital mortality.
Mechanical circulatory support (MCS) has transformed CS management.
The Impella device represents an advancement in MCS for CS.

Purpose of the Study:

To provide a comprehensive overview of the Impella device for CS.
To detail the rationale and physiological impact of ventricular unloading in CS.
To outline practical aspects for optimizing patient care with percutaneous circulatory support.

Main Methods:

Review of existing literature on Impella device and CS.
Analysis of the physiological mechanisms of ventricular unloading.
Discussion of clinical applications and patient management strategies.

Main Results:

The Impella device actively reduces ventricular volume and pressure, augmenting systemic blood flow.
It improves myocardial oxygen supply and systemic circulation, potentially aiding myocardial recovery.
Current evidence is largely observational, highlighting the need for randomized trials.

Conclusions:

The Impella device is a promising technology for managing CS patients.
Understanding the device, its impact, and clinical application is crucial for percutaneous circulatory support.
Ventricular unloading offers a therapeutic strategy to interrupt the shock spiral in CS.